All of DSpace

Show simple item record

Antiangiogenic strategies in hepatocellular carcinoma: current status

dc.creatorZacharoulis, D.en
dc.creatorHatzitheofilou, C.en
dc.creatorAthanasiou, E.en
dc.creatorZacharoulis, S.en
dc.date.accessioned2015-11-23T10:54:29Z
dc.date.available2015-11-23T10:54:29Z
dc.date.issued2005
dc.identifier10.1586/14737140.5.4.645
dc.identifier.issn1473-7140
dc.identifier.urihttp://hdl.handle.net/11615/34754
dc.description.abstractHepatocellular carcinoma is a leading cause of cancer death worldwide in both adult and pediatric patients. Despite many options, no ideal treatment exists for this highly malignant tumor, and management strategies have varied accordingly. Angiogenesis, the formation of new blood vessels, is an essential component of hepatocellular carcinoma biology. Innovative approaches such as targeting the nontransformed, less resistant, tumor-supporting endothelial cells are currently under investigation in hepatocellular carcinoma. This review will focus on the current knowledge of the pathophysiology of hepatocellular carcinoma angiogenesis, as well as the reported data with angiogenesis inhibitors against hepatocellular carcinoma.en
dc.sourceExpert Review of Anticancer Therapyen
dc.source.uri<Go to ISI>://WOS:000234106300007
dc.subjectqantiangiogenic strategiesen
dc.subjecthepatocellular carcinomaen
dc.subjectvascularen
dc.subjectendothelial growth factorsen
dc.subjectENDOTHELIAL GROWTH-FACTORen
dc.subjectTYROSINE KINASE INHIBITORen
dc.subjectHEPATITIS-C VIRUSen
dc.subjectCONVERTING ENZYME-INHIBITORen
dc.subjectPHASE-II TRIALen
dc.subjectINTERFERON-ALPHAen
dc.subjectTUMORen
dc.subjectANGIOGENESISen
dc.subjectPLASMINOGEN-ACTIVATORen
dc.subjectFACTOR EXPRESSIONen
dc.subjectIN-VITROen
dc.subjectOncologyen
dc.titleAntiangiogenic strategies in hepatocellular carcinoma: current statusen
dc.typejournalArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record